ABT · Earnings call · 2026Q3T · Full report

CGM Market Demand

ABBOTT LABORATORIES · 2026-10-21 · Importance 26 · Surprise 24

Management said clinical data supports continuous glucose monitoring for people with type 2 diabetes who do not use insulin, describing CGMs as tools that provide information to help change behavior. Abbott is preparing for potential adoption in this population by investing in primary care, a different channel from diabetes endocrinology clinics. Management did not forecast when CMS reimbursement might begin, but said it expects acceleration when it does.

Key facts

• Abbott said its CGM market share in major international countries ranges from 50% to 70%.
• Abbott’s continuous glucose monitoring sales grew 8% in the third quarter.
• Abbott said it has invested in primary care for some time in preparation for CGM use among non-insulin users, a different channel from diabetes endocrinology clinics.
• Abbott said clinical data supports CGM use for type 2 non-insulin-using patients and basal patients, and described CGMs as behavior-modification tools that provide information.